|
Name |
brevianamide V
|
Molecular Formula | C21H23N3O2 | |
IUPAC Name* |
(3Z,8aS)-3-[[2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl]methylidene]-6,7,8,8a-tetrahydropyrrolo[1,2-a]pyrazine-1,4-dione
|
|
SMILES |
CC(C)(C=C)C1=C(C2=CC=CC=C2N1)/C=C\3/C(=O)N4CCC[C@H]4C(=O)N3
|
|
InChI |
InChI=1S/C21H23N3O2/c1-4-21(2,3)18-14(13-8-5-6-9-15(13)22-18)12-16-20(26)24-11-7-10-17(24)19(25)23-16/h4-6,8-9,12,17,22H,1,7,10-11H2,2-3H3,(H,23,25)/b16-12-/t17-/m0/s1
|
|
InChIKey |
OLIPWSSLWWMAAT-WBILKINKSA-N
|
|
Synonyms |
brevianamide V; (3Z,8aS)-3-[[2-(1,1-dimethylallyl)-1H-indol-3-yl]methylene]-6,7,8,8a-tetrahydropyrrolo[1,2-a]pyrazine-1,4-dione
|
|
CAS | NA | |
PubChem CID | 71480344 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 349.4 | ALogp: | 3.6 |
HBD: | 2 | HBA: | 2 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 65.2 | Aromatic Rings: | 4 |
Heavy Atoms: | 26 | QED Weighted: | 0.652 |
Caco-2 Permeability: | -4.923 | MDCK Permeability: | 0.00002460 |
Pgp-inhibitor: | 0.996 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.057 |
30% Bioavailability (F30%): | 0.003 |
Blood-Brain-Barrier Penetration (BBB): | 0.034 | Plasma Protein Binding (PPB): | 97.01% |
Volume Distribution (VD): | 0.65 | Fu: | 1.53% |
CYP1A2-inhibitor: | 0.582 | CYP1A2-substrate: | 0.822 |
CYP2C19-inhibitor: | 0.762 | CYP2C19-substrate: | 0.113 |
CYP2C9-inhibitor: | 0.825 | CYP2C9-substrate: | 0.924 |
CYP2D6-inhibitor: | 0.822 | CYP2D6-substrate: | 0.861 |
CYP3A4-inhibitor: | 0.863 | CYP3A4-substrate: | 0.514 |
Clearance (CL): | 3.153 | Half-life (T1/2): | 0.588 |
hERG Blockers: | 0.022 | Human Hepatotoxicity (H-HT): | 0.404 |
Drug-inuced Liver Injury (DILI): | 0.774 | AMES Toxicity: | 0.085 |
Rat Oral Acute Toxicity: | 0.424 | Maximum Recommended Daily Dose: | 0.632 |
Skin Sensitization: | 0.082 | Carcinogencity: | 0.611 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.039 |
Respiratory Toxicity: | 0.884 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004932 | 1.000 | D0U7GK | 0.326 | ||||
ENC004928 | 0.762 | D0Q5NX | 0.313 | ||||
ENC002714 | 0.682 | D05MQK | 0.287 | ||||
ENC004441 | 0.667 | D0A3ZU | 0.280 | ||||
ENC004440 | 0.667 | D08VRO | 0.279 | ||||
ENC002715 | 0.659 | D01PZD | 0.278 | ||||
ENC001957 | 0.655 | D0U7GP | 0.276 | ||||
ENC005569 | 0.655 | D01JGV | 0.276 | ||||
ENC000981 | 0.640 | D06GKN | 0.271 | ||||
ENC004933 | 0.640 | D0H4JM | 0.265 |